Takeda’s Dual-Drug Crohn’s Study Could Reframe Entyvio’s Role in IBD Portfolios
Takeda Pharmaceutical Company (TAK) announced an update on their ongoing clinical study.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Takeda (TAK) is running a Phase 4 study in adults with moderate to severe Crohn’s disease to test dual targeted therapy with Entyvio (vedolizumab) plus Humira (adalimumab) or Stelara (ustekinumab), followed by Entyvio alone in responders. The open-label trial aims to see if pairing these drugs can improve control of symptoms and then maintain benefits on single therapy, which could support broader real-world use.
The study tests three active treatment paths. In Part A, patients receive Entyvio with either Humira or Stelara to see if the combination brings better short-term disease control, while Part B moves qualifying patients to Entyvio alone to check if gains can be sustained with one drug and a simpler long-term regimen.
The design is interventional and non-randomized, with two parallel groups on different drug pairs and no placebo arm, which keeps the approach closer to real-world practice. There is no blinding, so both doctors and patients know which drugs are given, and the main goal is treatment benefit rather than prevention or diagnosis, making outcomes easier to apply in routine care.
The trial began enrolling after initial submission on 13 September 2023, and it is currently recruiting, so near-term results are not yet available for the market to price in. The last update on 17 March 2026 signals that the protocol and status were recently reviewed, which is a useful marker for investors tracking operational progress and timing of future data.
For Takeda, positive signals could reinforce Entyvio’s role in Crohn’s and support higher penetration in complex patients, which may underpin sentiment on TAK as investors look for durable gastroenterology revenue. The dual therapy angle also intersects with AbbVie’s Humira and Johnson & Johnson’s Stelara, so any evidence that Entyvio pairs well or anchors maintenance therapy could shape competitive positioning across the inflammatory bowel disease class.
The study remains ongoing and recently updated, and investors can find further operational and design details on the ClinicalTrials.gov portal under the listed identifier.
To learn more about TAK’s potential, visit the Takeda Pharmaceutical Company drug pipeline page.
